Recent Quotes (30 days)

You have no recent quotes
chg | %

Revive Therapeutics Ltd  

(Public, CVE:RVV)   Watch this stock  
Find more results for RVV
-0.035 (-7.00%)
Sep 1 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.47 - 0.47
52 week 0.40 - 1.00
Open 0.47
Vol / Avg. 1,000.00/6,405.00
Mkt cap 11.13M
P/E     -
Div/yield     -
EPS -0.09
Shares 23.94M
Beta     -
Inst. own     -

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -70.69% -152.87%
Return on average equity -74.25% -162.05%
CDP Score - -


5 Director Court, Suite 105
+1-905-6055535 (Phone)

Website links


Revive Therapeutics Ltd., formerly Mercury Capital II Limited, is focused on acquiring, developing and commercializing treatments for major market opportunities such as sleep apnea, gout and rare diseases. The Company is focused on underserved medical needs such as opioid-induced respiratory depression in high risk patients with sleep apnea, gout, and Rett Syndrome. The Company is also developing a next generation analog of REV-001, which is an improvement of the original compound and it will have the potential to treat new diseases that would otherwise remain untreated with the original compound, such as rare diseases, breathing disorders, and cognitive dysfunction.

Officers and directors

Thomas Sears Chief Executive Officer, Chief Financial Officer, Director
Age: 34
Robbie Grossman Secretary, Director
Age: 40
Scott Johnson Director
Age: 36
Anton Konovalov Director
Age: 26
Reiza Rayman M.D. Director
Age: 51
Carlo Sansalone Director
Age: 35